1-8 of 8
Merja Suominen
Close
Sort by
Journal Articles

RVD + ASCT + Lenalidomide Maintenance Benefits Patients without High-Risk Cytogenetics and Results in Recovery of the Normal Plasma Cell Composition in Bone Marrow

Raija Silvennoinen, MD, Pekka Anttila, MD, Marjaana Säily, MD PhD, Tuija Lundan, PhD, Jouni Heiskanen, MD, Timo Siitonen, MD PhD, Sakari Kakko, MD PhD, Mervi Putkonen, MDPhD, Hanna Ollikainen, MD, Venla Terävä, MD, Anu Partanen, MD, Kirsi Launonen, MD, Anu Räsänen, MD, Anu Sikiö, MD, Merja Suominen, MD, Piotr Bazia, MD, Kristiina Kananen, MD PhD, Juha Lievonen, MD, Tuomas Selander, MSc, Imre Västrik, Dr, PhD, Tarja-Terttu Pelliniemi, MD PhD, Kimmo Porkka, MD PhD, Kari Remes, MD PhD, Esa Jantunen, MD PhD
Journal: Blood
Blood (2016) 128 (22): 676.
https://doi.org/10.1182/blood.V128.22.676.676
Published: 2016
Journal Articles

A Prospective Phase 2 Study to Assess Immunophenotypic Remission after Lenalidomide-Based Induction Followed By ASCT and Lenalidomide Maintenance in Patients with Newly Diagnosed Multiple Myeloma

Raija Silvennoinen, MD, Pekka Anttila, MD, Marjaana Säily, MD PhD, Tuija Lundan, PhD, Jouni Heiskanen, MD, Timo Siitonen, MD PhD, Sakari Kakko, MD PhD, Mervi Putkonen, MDPhD, Hanna Ollikainen, MD, Venla Terävä, MD, Anu Partanen, MD, Kirsi Launonen, MD, Anu Räsänen, MD, Anu Sikiö, MD, Merja Suominen, MD, Piotr Bazia, MD, Kristiina Kananen, MD PhD, Tuomas Selander, MSc, Taru Kuittinen, MD PhD, Kimmo Porkka, MD PhD, Kari Remes, MDPhD, Esa Jantunen, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1977.
https://doi.org/10.1182/blood.V126.23.1977.1977
Published: 2015
Journal Articles

A Randomized Comparison of Low-Dose Cyclophosphamide + G-CSF Versus G-CSF Alone Mobilization after Lenalidomide-Bortezomib-Dexamethasone (RVD) Induction in Multiple Myeloma

Raija Silvennoinen, MD, Tuija Lundan, PhD, Pekka Anttila, MD, Jouni Heiskanen, MD, Marjaana Säily, MDPhD, Timo Siitonen, MDPhD, Sakari Kakko, MDPhD, Hanna Ollikainen, MD, Seppo Vanhatalo, MD, Mervi Putkonen, MDPhD, Venla Terävä, MD, Anu Kutila, MD, Mari Partio, MD, Kirsi Launonen, MD, Anu Räsänen, MD, Anu Sikiö, MD, Merja Suominen, MD, Piotr Bazia, MD, Kristiina Kananen, MDPhD, Taru Kuittinen, MD PhD, Kimmo Porkka, MD PhD, Kari Remes, MD PhD, Esa Jantunen, MDPhD
Journal: Blood
Blood (2014) 124 (21): 847.
https://doi.org/10.1182/blood.V124.21.847.847
Published: 2014
Journal Articles

Rituximab Maintenance Bimonthly for Two Years after Prolonged Immunochemotherapy in Elderly Patients with Mantle Cell Lymphoma (MCL) Results in Long Remissions: Update with Six-Year Follow-up of a Prospective Study By the Finnish Lymphoma Group

Riikka Räty, Tuomo Honkanen, Esa Jantunen, MDPhD, Sirkku Jyrkkiö, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Outi Kuittinen, Minna Lehto, Maija Mikkola, Eira Poikonen, Auvo Rauhala, Johanna Rimpiläinen, Anu Räsänen, MD, Sanna Siitonen, Merja Suominen, MD, Mirja Vapaatalo, Erkki Elonen
Journal: Blood
Blood (2014) 124 (21): 1749.
https://doi.org/10.1182/blood.V124.21.1749.1749
Published: 2014
Journal Articles

Dasatinib Treatment Induces Fast and Deep Responses In Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients In Chronic Phase: Clinical Results From a Randomized Phase 2 Study (NordCML006)

Henrik Hjorth-Hansen, MD, PhD, Johan Richter, MD, PhD, Leif Stenke, MD, PhD, Hans Ehrencrona, MD, PhD, Bjørn Tore Gjertsen, MD, PhD, Tobias Gedde-Dahl, III, MD, PhD, Perttu Koskenvesa, MD, Claes Malm, MD, Waleed Majeed, MD, Lotta Ohm, MD PhD, Martin Hoglund, MD PhD, Ulla Olsson-Strömberg, MD, PhD, Stina Söderlund, MD, Merja Suominen, MD, Kari Remes, MD PhD, Berit Markevärn, MD, Bengt Simonsson, MD PhD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4032.
https://doi.org/10.1182/blood.V122.21.4032.4032
Published: 2013
Journal Articles

Favorable Therapeutic Responses in Newly Diagnosed CML-CP Patients Induced by Dasatinib Are Reflected At the CD34+CD38+ Progenitor Cell but Not At the CD34+CD38− Stem Cell Level: Results From Randomized NordCML006 Study

Satu Mustjoki, MD, PhD, Johan Richter, MD, PhD, Gisela Barbany, MD, PhD, Hans Ehrencrona, MD, PhD, Ingunn Dybedal, MD, PhD, Thoas Fioretos, MD, PhD, Tobias Gedde-Dahl, MD, PhD, Bjorn Gjertsen, MD, PhD, Randi Hovland, PhD, Sari E Jalkanen, MSc, Dag Josefsen, MD, PhD, Perttu Koskenvesa, MD, Carin Lassen, Msc, Kirsi Latvala, Waleed Majeed, MD, Claes Malm, MD, Berit Markevärn, MD, Ali Mosfegh, PhD, Lotta Ohm, MD, Tor Olofsson, MD, PhD, Ulla Olsson-Strömberg, MD, PhD, Katrin Rapakko, PhD, Kari Remes, MD PhD, Jesper Stentoft, MD, PhD, Leif Stenke, MD, PhD, Merja Suominen, MD, Sara Thunberg, PhD, Ole Weiss Bjerrum, MD, PhD, Bengt Simonsson, MD, PhD, Kimmo Porkka, MD, PhD, Henrik Hjorth-Hansen, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 784.
https://doi.org/10.1182/blood.V118.21.784.784
Published: 2011
Journal Articles

The Proportion of Ph+ CD34 + CD38 neg Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI-Therapy. Data From a Randomized Phase II NordCML006 Study

Satu Mustjoki, MD, PhD, Johan Richter, MD, PhD, Gisela Barbany, MD, PhD, Ingunn Dybedal, MD, PhD, Thoas Fioretos, MD, PhD, Tobias Gedde-Dahl, MD, PhD, Bjorn T. Gjertsen, MD, PhD, Randi Hovland, PhD, Sari Jalkanen, Msc, Dag Josefsen, MD, PhD, Perttu Koskenvesa, MD, Carin Lassen, Kirsi Latvala, Waleed Majeed, MD, Claes Malm, MD, Berit Markevärn, MD, Ali Moshfegh, PhD, Lotta Ohm, MD, Tor Olofsson, MD, PhD, Ulla Olsson-Strömberg, MD, PhD, Katrin Rapakko, PhD, Kari Remes, MD, PhD, Jesper Stentoft, MD, PhD, Leif Stenke, MD, PhD, Merja Suominen, MD, Sara Thunberg, MD, PhD, Ole Weiss Bjerrum, MD, PhD, Bengt Simonsson, MD, PhD, Kimmo Porkka, MD, PhD, Henrik Hjorth-Hansen, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 667.
https://doi.org/10.1182/blood.V116.21.667.667
Published: 2010
Journal Articles

Elderly Patients with Mantle Cell Lymphoma (MCL) – Efficacy and Feasibility of Prolonged Immunochemotherapy with Rituximab, Cytarabine and Fludarabine Added to CHOP and Followed by Rituximab Maintenance Treatment. A Prospective Study by the Finnish Lymphoma Group

Erkki Elonen, Riikka Räty, Tuomo Honkanen, Esa Jantunen, Sirkku Jyrkkiö, Marja-Liisa Karjalainen-Lindsberg, Outi Kuittinen, Minna Lehto, Eira Poikonen, Auvo Rauhala, Johanna Rimpiläinen, Anu Räsänen, Sanna Siitonen, Merja Suominen, Mirja Vapaatalo
Journal: Blood
Blood (2008) 112 (11): 1001.
https://doi.org/10.1182/blood.V112.11.1001.1001
Published: 2008